Joo D. Park
Gyeonggi-do, Republic of Korea
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 15 publications
Biomimetic lipid nanoparticles for macrophage reprogramming in cancer immunotherapy.
Journal: Journal of controlled release : official journal of the Controlled Release Society
Published: February 12, 2026
Transforming lipid nanoparticles into radio-activatable therapeutics through synergistic ferroptosis for enhanced cancer radiotherapy.
Journal: Biomaterials
Published: October 19, 2025
Photosensitizing Lipid Nanoparticles for Ferroptosis-Enhanced Photodynamic Cancer Therapy via GPX4 Silencing.
Journal: Advanced healthcare materials
Published: August 01, 2025
Synergistic immunotherapeutic effects of irreversible electroporation and CAR-NK cell therapy against hepatocellular carcinoma.
Journal: Signal transduction and targeted therapy
Published: May 28, 2025
Correction: ELK3-CYFIP2 axis-mediated actin remodeling modulates metastasis and natural killer cell responses in triple-negative breast cancer.
Journal: Journal of experimental & clinical cancer research : CR
Published: April 16, 2025
Lipid nanoparticles target neutrophils to reduce SARS-CoV-2-induced lung injury and inflammation.
Journal: Journal of controlled release : official journal of the Controlled Release Society
Published: December 15, 2024
Dual-Functional Hafnium Oxide Nanoplatform Combining High-Z Radiosensitization With Bcl-2 Gene Silencing for Enhanced Cancer Radiotherapy.
Journal: Advanced healthcare materials
Published: December 01, 2024
ELK3-CYFIP2 axis-mediated actin remodeling modulates metastasis and natural killer cell responses in triple-negative breast cancer.
Journal: Journal of experimental & clinical cancer research : CR
Published: August 16, 2024
Advancing Natural Killer Cell Therapy: Genetic Engineering Strategies for Enhanced Cancer Immunotherapy.
Journal: Annals of laboratory medicine
Published: July 19, 2024
ELK3-ID4 axis governs the metastatic features of triple negative breast cancer.
Journal: Oncology research
Published: June 17, 2023
The ELK3-DRP1 axis determines the chemosensitivity of triple-negative breast cancer cells to CDDP by regulating mitochondrial dynamics.
Journal: Cell death discovery
Published: April 03, 2023
ELK3-CXCL16 axis determines natural killer cell cytotoxicity via the chemotactic activity of CXCL16 in triple negative breast cancer.
Journal: Oncoimmunology
Published: March 23, 2023
Last Updated: 09/26/2026